原发性中枢神经系统淋巴瘤患者的癫痫:患病率、危险因素与预后意义
这项单中心回顾性观察研究纳入2011至2023年间330例免疫功能正常、无癫痫史的原发性中枢神经系统淋巴瘤(PCNSL)患者,83例(25.2%)在病程中出现至少1次癫痫发作。皮质接触(OR 8.6,95%CI 4.2-15.5,p<0.001)和高增殖指数(OR 5.7,95%CI 1.3-26.2,p=0.02)为独立危险因素;合并癫痫者无进展生存期更短(中位9.6 vs 14.1个月,校正HR 1.4,95%CI 1.0-1.9,p=0.03),总生存期无显著差异(17 vs 44.1个月,log-rank p=0.09)。
要点
- PCNSL患者中25.2%出现癫痫发作,12.1%以癫痫为首发症状,8.2%发生于肿瘤进展时。
- 皮质接触与高增殖指数是PCNSL相关癫痫的独立危险因素。
- 合并癫痫者无进展生存期更短,但总生存期无显著差异。
核心结论
- 癫痫影响约四分之一PCNSL患者,半数在初诊时出现,可能作为疾病进展的标志。
研究设计与样本
- 单中心回顾性观察研究,纳入2011至2023年一家三级神经肿瘤中心的330例免疫功能正常、无癫痫史的PCNSL患者。
主要发现
- 83例(25.2%)从初诊至末次随访出现至少1次癫痫发作,其中40例(12.1%)以癫痫为首发症状,16例(4.8%)发生于一线治疗期间,27例(8.2%)发生于肿瘤进展时,6例(1.8%)发生于缓解期。
- 局灶性意识清醒发作最常见,发生于43例(51.8%)患者;抗癫痫药物治疗后97.6%患者达到无发作。
- 皮质接触(OR 8.6,95%CI 4.2-15.5,p<0.001)和高增殖指数(OR 5.7,95%CI 1.3-26.2,p=0.02)为癫痫的独立危险因素。
- 合并癫痫的PCNSL患者无进展生存期显著更短(中位9.6 vs 14.1个月,校正HR 1.4,95%CI 1.0-1.9,p=0.03),总生存期无显著差异(17 vs 44.1个月,log-rank检验p=0.09)。
局限性
- 研究结论受回顾性设计限制。
- 研究结论受三级中心设置限制。
- 需进一步研究以评估这些发现的更广泛适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Epilepsy is a common comorbidity of brain tumors; however, little is known about the prevalence, onset time, semiology, and risk factors of seizures in primary CNS lymphoma (PCNSL). Our objectives were to determine the prevalence of epilepsy in PCNSL, to identify factors associated with epilepsy, and to investigate the prognostic significance of seizures in PCNSL. METHODS: We performed an observational, retrospective single-center study at a tertiary neuro-oncology center (2011-2023) including immunocompetent patients with PCNSL and no history of seizures. We collected clinical, imaging, and treatment data; seizure status over the course of PCNSL; and oncological and seizure outcome. The primary outcome was to determine the prevalence of epilepsy. Furthermore, we aimed to identify clinical, radiologic, and treatment-related factors associated with epilepsy. Univariate analyses were conducted using the χ2 test for categorical variables and unpaired t test for continuous variables. Predictors identified in the unadjusted analysis were included in backward stepwise logistic regression models. RESULTS: We included 330 patients, 157 (47.6%) were male, median age at diagnosis was 68 years, and the median Karnofsky Performance Status score was 60. Eighty-three (25.2%) patients had at least 1 seizure from initial diagnosis to the last follow-up, 40 (12.1%) as the onset symptom, 16 (4.8%) during first line of treatment, 27 (8.2%) at tumor progression and 6 (1.8%) while in remission. Focal aware seizures were the most frequent seizure type, occurring in 43 (51.8%) patients. Seizure freedom under antiseizure medication was observed in 97.6% patients. Cortical contact (odds ratio [OR] 8.6, 95% CI 4.2-15.5, p < 0.001) and a higher proliferation index (OR 5.7, 95% CI 1.3-26.2, p = 0.02) were identified as independent risk factors of epilepsy. Patients with PCNSL and epilepsy had a significantly shorter progression-free survival (median progression-free survival 9.6 vs 14.1 months, adjusted hazard ratio 1.4, 95% CI 1.0-1.9, p = 0.03), but not a significantly shorter overall survival (17 vs 44.1 months, log-rank test, p = 0.09). DISCUSSION: Epilepsy affects a quarter of patients with PCNSL, with half experiencing it at the time of initial presentation and potentially serving as a marker of disease progression. Further research is necessary to assess the broader applicability of these findings because they are subject to the constraints of a retrospective design and tertiary center setting.
引用
- Aboubakr O, Houillier C, Alentorn A, et al. Epilepsy in Patients With Primary CNS Lymphoma: Prevalence, Risk Factors, and Prognostic Significance. Neurology. 2024. PMID: 39116374. doi:10.1212/WNL.0000000000209748
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。